These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 2982011)

  • 1. Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation.
    Tempel A; Gardner EL; Zukin RS
    J Pharmacol Exp Ther; 1985 Feb; 232(2):439-44. PubMed ID: 2982011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonist-induced up-regulation of the putative epsilon opioid receptor in rat brain: comparison with kappa, mu and delta opioid receptors.
    Giordano AL; Nock B; Cicero TJ
    J Pharmacol Exp Ther; 1990 Nov; 255(2):536-40. PubMed ID: 2173747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paradoxical and subtype-specific effects of opiate antagonists on the expression of opioid receptors in rat brain cultures.
    Barg J; Levy R; Simantov R
    J Neurosci Res; 1989 Mar; 22(3):322-30. PubMed ID: 2540341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma corticosterone changes in response to central or peripheral administration of kappa and sigma opiate agonists.
    Eisenberg RM
    J Pharmacol Exp Ther; 1985 Jun; 233(3):863-9. PubMed ID: 2989500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decrease in delta and mu opioid receptor binding capacity in rat brain after chronic etorphine treatment.
    Tao PL; Law PY; Loh HH
    J Pharmacol Exp Ther; 1987 Mar; 240(3):809-16. PubMed ID: 3031275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naltrexone-induced opiate receptor supersensitivity.
    Zukin RS; Sugarman JR; Fitz-Syage ML; Gardner EL; Zukin SR; Gintzler AR
    Brain Res; 1982 Aug; 245(2):285-92. PubMed ID: 6289965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
    Yoburn BC; Purohit V; Patel K; Zhang Q
    Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice.
    Ward SJ; Takemori AE
    J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-regulation of delta opioid receptors in neuroblastoma hybrid cells: evidence for differences in the mechanisms of action of sodium butyrate and naltrexone.
    Belcheva MM; Barg J; McHale RJ; Gao XM; Chuang DM; Coscia CJ
    J Pharmacol Exp Ther; 1991 Oct; 259(1):302-9. PubMed ID: 1656025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mu opiate receptor down-regulation by morphine and up-regulation by naloxone in SH-SY5Y human neuroblastoma cells.
    Zadina JE; Chang SL; Ge LJ; Kastin AJ
    J Pharmacol Exp Ther; 1993 Apr; 265(1):254-62. PubMed ID: 8097244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in guinea-pig isolated ileum.
    Capasso A; Sorrentino L
    Br J Pharmacol; 1997 Mar; 120(6):1001-6. PubMed ID: 9134209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solubilization and preliminary characterization of mu and kappa opiate receptor subtypes from rat brain.
    Chow T; Zukin RS
    Mol Pharmacol; 1983 Sep; 24(2):203-12. PubMed ID: 6310362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of opioid receptor density in morphine tolerance.
    Lutfy K; Yoburn BC
    J Pharmacol Exp Ther; 1991 Feb; 256(2):575-80. PubMed ID: 1847202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paradoxical effect of chronic fentanyl treatment on naltrexone-induced supersensitivity and upregulation.
    Ayesta FJ; Ableitner A; Emmett-Oglesby MW; Herz A; Shippenberg TS
    J Pharmacol Exp Ther; 1992 Jan; 260(1):168-74. PubMed ID: 1731036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective and interactive down-regulation of mu- and delta-opioid receptors in human neuroblastoma SK-N-SH cells.
    Baumhaker Y; Gafni M; Keren O; Sarne Y
    Mol Pharmacol; 1993 Aug; 44(2):461-7. PubMed ID: 8394999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence.
    Wang D; Raehal KM; Lin ET; Lowery JJ; Kieffer BL; Bilsky EJ; Sadée W
    J Pharmacol Exp Ther; 2004 Feb; 308(2):512-20. PubMed ID: 14600246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
    Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
    J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of a new opiate antagonist, nalmefene, to rat brain membranes.
    Michel ME; Bolger G; Weissman BA
    Methods Find Exp Clin Pharmacol; 1985 Apr; 7(4):175-7. PubMed ID: 2991678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naloxazone, a long-acting opiate antagonist: effects on analgesia in intact animals and on opiate receptor binding in vitro.
    Pasternak GW; Childers SR; Snyder SH
    J Pharmacol Exp Ther; 1980 Sep; 214(3):455-62. PubMed ID: 6105201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
    Wang HY; Friedman E; Olmstead MC; Burns LH
    Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.